Article

Follicular mucinosis in a teenage girl.

Dept of Dermatovenereology, University Medical Centre Ljubljana, Zaloska 2, 1525 Ljubljana, Slovenia.
Acta dermatovenerologica Alpina, Panonica, et Adriatica 10/2005; 14(3):111-4.
Source: PubMed

ABSTRACT Follicular mucinosis is characterized by mucin deposits within the hair follicles and sebaceous glands. It can occur as a primary idiopathic benign disorder; it can be found as an incidental phenomenom in rare cases of different dermatoses; or it can arise as a secondary symptom of a malignant disorder, most commonly mycosis fungoides. Youth and localization in a single area used to be regarded as indicative of the benign nature of follicular mucinosis. However, recent reports demonstrate that no clear-cut criteria allow for the differentiation of idiopathic from lymphoma-associated follicular mucinosis. We report the case of a 16-year old girl who presented with a 2-year history of a single, slightly pruritic, erythematous patch on the left side of the neck. Different local treatments (local corticosteroids, antibiotics, antifungal ointments and moisturizers) were ineffective. Overall, she was healthy. Histopathological examination of the lesion showed the typical histological picture of follicular mucinosis.

1 Follower
 · 
251 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Eosinophilic pustular folliculitis (EPF) is a noninfectious eosinophilic infiltration of hair follicles first described 40 years ago. There are 3 variants: classic EPF, immunosuppression-associated (mostly HIV-related), and infancy-associated EPF. EPF has been classified as an AIDS-defining illness. In both children and adults EPF should be viewed as a possible cutaneous sign of immunosuppression. However, it may also be seen in persons with normal immune status. We review EPF on the 40th anniversary of its original description.
    Journal of the American Academy of Dermatology 09/2006; 55(2):285-9. DOI:10.1016/j.jaad.2006.02.034 · 5.00 Impact Factor
  • Piel 12/2006; 21(10):493-498. DOI:10.1016/S0213-9251(06)72547-3
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To study the clinical features, therapeutic responses, and outcomes in patients with folliculotropic mycosis fungoides (FMF) and to compare our single-center experience of 43 patients with the findings from the Dutch Cutaneous Lymphoma Group. A single-center experience from the Northwestern University Multidisciplinary Cutaneous Lymphoma Group. Forty-three patients with FMF were included in the study and compared with 43 age- and stage-matched patients with classic epidermotropic mycosis fungoides (MF) with similar follow-up time. Folliculotropic mycosis fungoides showed distinct clinical features, with 37 patients having facial involvement (86%) and only 6 having lesions limited to the torso (14%). The morphologic spectrum of lesions is broad and includes erythematous papules and plaques with follicular prominence with or without alopecia; comedonal, acneiform, and cystic lesions; alopecic patches with or without scarring; and nodular and prurigolike lesions. Sixty-five percent of patients had alopecia, which in 71% of cases involved the face. Severe pruritus was seen in 68% of patients. In general, patients responded poorly to skin-directed therapy and in almost all cases required systemic agents to induce even a partial remission, including patients with early-stage disease. Overall survival was poor. Patients with early-stage disease (< or =IIA) had a 10-year survival of 82%, which took a steep drop off to 41% by 15 years. Patients with late-stage disease (> or =IIB) had an outcome similar to those patients in the control group with conventional epidermotropic MF of a similar stage. The morphologic spectrum of clinical presentation for FMF is broad and distinct from those in conventional MF. This is at least partially attributed to the ability of FMF to simulate a variety of inflammatory conditions afflicting the follicular unit. The disease course is aggressive, and many patients, including those with early disease, show a poor outcome particularly between 10 and 15 years after the initial onset of disease. Response to skin-directed therapy is poor even in early-stage disease, and our best results were seen with psoralen plus UV-A (PUVA) therapy with oral bexarotene or PUVA with interferon alfa. These findings corroborate those of the Dutch Cutaneous Lymphoma Group and further validate the classification of FMF as a distinct entity.
    Archives of dermatology 06/2008; 144(6):738-46. DOI:10.1001/archderm.144.6.738 · 4.31 Impact Factor
Show more

Preview

Download
2 Downloads
Available from